Main Conference Day 2Thursday, 28 May 2026 - European Time GMT+1

Plasmodium falciparum malaria remains a global health problem. Here, I will discuss our efforts to identify and characterize human antibodies against Plasmodium falciparum targets including their clonal evolution and target epitopes to inform the development of improved malaria vaccines.

XmAb412 is a human, half-life–extended bispecific antibody that potently blocks interleukin-23 (IL-23p19) and TL1A, two cytokines that drive pathogenic T-cell responses in ulcerative colitis and Crohn’s disease. This presentation will highlight the discovery, engineering, AI-enhanced affinity maturation, and lead selection of XmAb412, as well as XmAb942, a related TL1A monospecific antibody currently in clinical development. In vitro data supporting clinical lead selection, along with pharmacokinetic and pharmacodynamic data supporting clinical translation and potential best-in-class activity, will be presented.

Autoantigen-specific IgA autoantibodies correlate with disease severity in autoimmune and fibrotic diseases. The presence IgA/autoantigen immune complexes result in continuous CD89-mediated activation of myeloid cells, leading to severe tissue damage. Activation of myeloid cells is a highly underappreciated and untargeted in autoimmune diseases. We developed an antagonist humanized anti-CD89 antibody (JJP-1212), that by interfering with the IgA/CD89 axis, resolves IgA/autoantigen-induced inflammation and subsequent tissue damage in autoimmune and fibrotic diseases.

Nucleome Therapeutics tackles the molecular causes of inflammatory diseases through a breakthrough approach to 3D human genetics. NTP464 is a novel inflammation checkpoint identified using Nucleome’s proprietary suite of genetic approaches. Through understanding how genetic variation in patients living with autoimmune disease impacts the genome’s physical 3D interactions with protein-coding genes, Nucleome has uncovered a profound multi-cellular orchestrator of inflammation resolution with potential to move beyond current advanced therapeutics.

Antibody-based approaches targeting respiratory viruses such as influenza and corona have gained momentum. Traditionally, efforts have focused on systemic or subcutaneous administration. More recently, focus has shifted to intranasal administration for protection at the portal of entry. Preclinical efficacy and human safety studies have explored the challenges and advantages of local antibody delivery.